Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 6/20 | 0.67 |
| ▸ | PYGM | P11217 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.47 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
| ▸ | TK2 | O00142 | 1/20 | 0.45 |
| ▸ | BCHE | P06276 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1469836 | 1.00 | TK1 (0.67) | TK1PYGMLMNASMN1; SMN2CYP1A2 | |
| SCHEMBL1469838 | 1.00 | TK1 (0.67) | TK1PYGMLMNASMN1; SMN2CYP1A2 | |
| SCHEMBL1469822 | 0.85 | TK1 (0.52) | TK1LMNATSHRBLMPMP22 | |
| SCHEMBL8296296 | 0.85 | TK1 (0.52) | TK1LMNATSHRBLMPMP22 | |
| SCHEMBL1469823 | 0.85 | TK1 (0.52) | TK1LMNATSHRBLMPMP22 | |
| SCHEMBL8907771 | 0.84 | TK1 (0.57) | TK1LMNASMN1; SMN2CYP1A2CYP3A4 | |
| SCHEMBL8292256 | 0.83 | TK1 (0.70) | TK1LMNASMN1; SMN2CYP1A2CYP3A4 | |
| Idoxuridine SCHEMBL9951400 | 0.80 | TK1 (1.00) | TK1PYGMLMNASMN1; SMN2CYP1A2 | |
| Idoxuridine SCHEMBL37714 | 0.80 | TK1 (1.00) | TK1PYGMLMNASMN1; SMN2CYP1A2 | |
| Idoxuridine SCHEMBL13252710 | 0.80 | TK1 (1.00) | TK1PYGMLMNASMN1; SMN2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0608809-B1 | Antiviral tetrahydropyrans | BRISTOL MYERS SQUIBB CO (US) | 1999-07-07 | — | — | EP | claimed |
| US-5607922-A | VIRICIDES AGAINST HERPES SIMPLEX, VACCINA OR VARICELLA ZOSTER | STICHTING REGA VZW (BE) | 1997-03-04 | — | — | US | claimed |
| US-10940150-B2 | Thymine derivatives and quinazoline-dione derivatives for the inhibition of HSP27 | TECHNISCHE UNIVERSITAET DRESDEN (DE) | 2021-03-09 | — | — | US | disclosed |
| US-20180207160-A1 | THYMINE DERIVATIVES AND QUINAZOLINE-DIONE DERIVATIVES FOR THE INHIBITION OF HSP27 | TECHNISCHE UNIVERSITAET DRESDEN (DE) | 2018-07-26 | — | — | US | disclosed |
| US-20170216297-A1 | EFFICIENT INHIBITION OF HSP27 | TECHNISCHE UNIVERSITAET DRESDEN (DE) | 2017-08-03 | — | — | US | disclosed |
| US-20170216297-A1 | EFFICIENT INHIBITION OF HSP27 | TECHNISCHE UNIVERSITAET DRESDEN (DE) | 2017-08-03 | — | — | US | disclosed |
| US-20080038745-A1 | NUCLEOTIDE ANALOGS WITH SIX-MEMBERED RINGS | BERGMANN FRANK | 2008-02-14 | — | — | US | disclosed |
| US-7276592-B2 | Nucleotide analogs with six-membered rings | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2007-10-02 | — | — | US | disclosed |
| US-20050004078-A1 | Nucleotide analogs with six-membered rings | ROCHE DIAGNOSTICS OPERATIONS, INC. | 2005-01-06 | — | — | US | disclosed |
| EP-1466919-A1 | Nucleotide analogs with six membered rings | Roche Diagnostics GmbH (DE) | 2004-10-13 | — | — | EP | disclosed |
| EP-0608809-B1 | Antiviral tetrahydropyrans | BRISTOL MYERS SQUIBB CO (US) | 1999-07-07 | — | — | EP | disclosed |
| EP-0646125-B1 | 1,5-ANHYDROHEXITOL NUCLEOSIDE ANALOGUES AND PHARMACEUTICAL USE THEREOF | STICHTING REGA V Z W (BE) | 1998-05-27 | — | — | EP | disclosed |
| US-5668113-A | Method of using 1,5-anhydrohexitol nucleoside analogues to treat viral infections | STICHTING REGA VZW (BE) | 1997-09-16 | — | — | US | disclosed |
| US-5607922-A | VIRICIDES AGAINST HERPES SIMPLEX, VACCINA OR VARICELLA ZOSTER | STICHTING REGA VZW (BE) | 1997-03-04 | — | — | US | disclosed |
| US-5414096-A | Antiviral tetrahydropyrans | BRISTOL-MYERS SQUIBB CO. (US) | 1995-05-09 | — | — | US | disclosed |
| EP-0646125-A1 | 1,5-ANHYDROHEXITOL NUCLEOSIDE ANALOGUES AND PHARMACEUTICAL USE THEREOF | Stichting REGA V.Z.W. (BE) | 1995-04-05 | — | — | EP | disclosed |
| EP-0608809-A1 | Antiviral tetrahydropyrans | BRISTOL-MYERS SQUIBB COMPANY (US) | 1994-08-03 | — | — | EP | disclosed |
| US-5314893-A | Antiviral tetrahydropyrans | BRISTOL-MYERS SQUIBB CO. (US) | 1994-05-24 | — | — | US | disclosed |
| WO-1993025565-A1 | 1,5-ANHYDROHEXITOL NUCLEOSIDE ANALOGUES AND PHARMACEUTICAL USE THEREOF | STICHTING REGA VZW (BE) | 1993-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180207160-A1 | THYMINE DERIVATIVES AND QUINAZOLINE-DIONE DERIVATIVES FOR THE INHIBITION OF HSP27 | HSPB1, HSP90B1, HSP90AB1 | TK1 213/4885PYGM 2321/4885LMNA 4404/4885 |
| US-20050004078-A1 | Nucleotide analogs with six-membered rings | NUDT1, TYMS, RNGTT | TK1 40/4885PYGM 3992/4885LMNA 778/4885 |
| US-20170216297-A1 | EFFICIENT INHIBITION OF HSP27 | HSPB1, HSP90AB2P, HSP90B1 | TK1 710/4885PYGM 2182/4885LMNA 4242/4885 |
| US-20080038745-A1 | NUCLEOTIDE ANALOGS WITH SIX-MEMBERED RINGS | NUDT1, TYMS, RNGTT | TK1 40/4885PYGM 3992/4885LMNA 778/4885 |
| US-10940150-B2 | Thymine derivatives and quinazoline-dione derivatives for the inhibition of HSP27 | HSPB1, HSP90B1, HSP90AB1 | TK1 213/4885PYGM 2321/4885LMNA 4404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.